Details
Stereochemistry | ACHIRAL |
Molecular Formula | C2H6O3S2 |
Molecular Weight | 142.197 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OS(=O)(=O)CCS
InChI
InChIKey=ZNEWHQLOPFWXOF-UHFFFAOYSA-N
InChI=1S/C2H6O3S2/c3-7(4,5)2-1-6/h6H,1-2H2,(H,3,4,5)
Molecular Formula | C2H6O3S2 |
Molecular Weight | 142.197 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including:
http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8c79a07d-32cc-4fe7-9a74-152c169f1c4f
http://www.drugbank.ca/drugs/DB09110
https://en.wikipedia.org/wiki/Mesna
Curator's Comment: description was created based on several sources, including:
http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8c79a07d-32cc-4fe7-9a74-152c169f1c4f
http://www.drugbank.ca/drugs/DB09110
https://en.wikipedia.org/wiki/Mesna
Mesna is an organosulfur compound used as an adjuvant in cancer chemotherapy involving cyclophosphamide and ifosfamide. No clinical drug interaction studies have been conducted with mesna. Mesna concentrates in the bladder where acrolein accumulates after administration of chemotherapy and through a Michael addition, forms a conjugate with acrolein and other urotoxic metabolites. This conjugation reaction inactivates the urotoxic compounds to harmless metabolites. The most common adverse reactions (> 10%) when MESNEX is given with ifosfamide are nausea, vomiting, constipation, leukopenia, fatigue, fever, anorexia, thrombocytopenia, anemia, granulocytopenia, diarrhea, asthenia, abdominal pain, headache, alopecia, and somnolence.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL721: Aerolein |
|||
Target ID: CHEMBL733: 4-Hydroxyifosfamide |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Secondary | MESNEX Approved UseMesna Injection is indicated as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis. Limitation of Use: Mesna Injection is not indicated to reduce the risk of hematuria due to other pathological conditions such as thrombocytopenia. Mesna Injection is a cytoprotective agent indicated as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis. (1) Limitation of Use: Mesna Injection is not indicated to reduce the risk of hematuria due to other pathological conditions such as thrombocytopenia. (1) Launch Date5.9944318E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
33 μM EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/8462128 |
1.2 g single, oral dose: 1.2 g route of administration: Oral experiment type: SINGLE co-administered: |
MESNA blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
511 μM EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/8462128 |
1.2 g single, intravenous dose: 1.2 g route of administration: Intravenous experiment type: SINGLE co-administered: |
MESNA blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
79 μM EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/9469350 |
0.24 g/m² single, intravenous dose: 0.24 g/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
MESNA blood | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
110 μM × h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/8462128 |
1.2 g single, oral dose: 1.2 g route of administration: Oral experiment type: SINGLE co-administered: |
MESNA blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
201 μM × h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/8462128 |
1.2 g single, intravenous dose: 1.2 g route of administration: Intravenous experiment type: SINGLE co-administered: |
MESNA blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
49 μM × h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/9469350 |
0.24 g/m² single, intravenous dose: 0.24 g/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
MESNA blood | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
92 min EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/9469350 |
0.24 g/m² single, intravenous dose: 0.24 g/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
MESNA blood | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Other AEs: Headache, Hypoaesthesia... Other AEs: Headache (43.8%) Sources: Hypoaesthesia (0%) Malaise (0%) Myalgia (0%) Nausea (0%) Pharyngitis (0%) Somnolence (6.3%) Upper respiratory infection (0%) Vomiting (0%) Dizziness (6.3%) Abdominal pain (6.3%) Coughing (0%) Diarrhea (6.3%) Anorexia (0%) Flushing (12.5%) Injection site reaction (12.5%) Back pain (6.3%) Dyspepsia (12.5%) Paraesthesia (6.3%) Renal pain (6.3%) Rigors (12.5%) Fatigue (0%) Conjunctivitis (6.3%) Arthralgia (12.5%) Application site reaction (31.3%) Photophobia (18.8%) Dehydration (6.3%) Dysuria (6.3%) Sweating increased (6.3%) |
2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Other AEs: Headache, Hypoaesthesia... Other AEs: Headache (33.3%) Sources: Hypoaesthesia (0%) Malaise (8.3%) Myalgia (0%) Nausea (16.7%) Pharyngitis (0%) Somnolence (8.3%) Upper respiratory infection (0%) Vomiting (16.7%) Dizziness (8.3%) Abdominal pain (8.3%) Coughing (0%) Diarrhea (0%) Anorexia (8.3%) Flushing (0%) Injection site reaction (0%) Back pain (0%) Dyspepsia (0%) Paraesthesia (8.3%) Renal pain (0%) Rigors (0%) Fatigue (8.3%) Conjunctivitis (0%) Arthralgia (0%) Application site reaction (0%) Photophobia (0%) Dehydration (0%) Dysuria (0%) Sweating increased (0%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Anorexia | 0% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Coughing | 0% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Fatigue | 0% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Hypoaesthesia | 0% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Malaise | 0% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Myalgia | 0% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Nausea | 0% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Pharyngitis | 0% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Upper respiratory infection | 0% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Vomiting | 0% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Arthralgia | 12.5% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Dyspepsia | 12.5% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Flushing | 12.5% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Injection site reaction | 12.5% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Rigors | 12.5% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Photophobia | 18.8% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Application site reaction | 31.3% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Headache | 43.8% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Abdominal pain | 6.3% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Back pain | 6.3% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Conjunctivitis | 6.3% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Dehydration | 6.3% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Diarrhea | 6.3% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Dizziness | 6.3% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Dysuria | 6.3% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Paraesthesia | 6.3% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Renal pain | 6.3% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Somnolence | 6.3% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Sweating increased | 6.3% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Application site reaction | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Arthralgia | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Back pain | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Conjunctivitis | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Coughing | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Dehydration | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Diarrhea | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Dyspepsia | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Dysuria | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Flushing | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Hypoaesthesia | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Injection site reaction | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Myalgia | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Pharyngitis | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Photophobia | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Renal pain | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Rigors | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Sweating increased | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Upper respiratory infection | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Nausea | 16.7% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Vomiting | 16.7% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Headache | 33.3% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Abdominal pain | 8.3% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Anorexia | 8.3% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Dizziness | 8.3% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Fatigue | 8.3% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Malaise | 8.3% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Paraesthesia | 8.3% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Somnolence | 8.3% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Prevention of isophosphamide-induced urothelial toxicity with 2-mercaptoethane sulphonate sodium (mesnum) in patients with advanced carcinoma. | 1980 Sep 27 |
|
Phase II trial of ifosfamide with mesna in previously treated metastatic sarcoma. | 1985 May |
|
Central nervous system toxicity following the treatment of pediatric patients with ifosfamide/mesna. | 1986 Aug |
|
Avoiding ifosfamide/mesna encephalopathy. | 1986 Aug 16 |
|
Blurring of vision due to ifosfamide. | 1987 |
|
Irreversible encephalopathy with ifosfamide/mesna. | 1987 Aug |
|
Encephalopathy with rapid infusion ifosfamide/mesna. | 1987 Feb 14 |
|
Chloroacetaldehyde and its contribution to urotoxicity during treatment with cyclophosphamide or ifosfamide. An experimental study/short communication. | 1989 Jun |
|
Dana-Farber Cancer Institute studies in advanced sarcoma. | 1990 Feb |
|
Placebo-controlled double-blind comparative study on the preventive efficacy of mesna against ifosfamide-induced urinary disorders. | 1991 |
|
Mesna versus hyperhydration for the prevention of cyclophosphamide-induced hemorrhagic cystitis in bone marrow transplantation. | 1991 Nov |
|
Ifosfamide with mesna in squamous carcinoma of the cervix: phase II results in patients with advanced or recurrent disease. | 1991 Nov |
|
Primary tumour mutant p53 gene protein and epidermal growth factor receptor expression and doxorubicin plus ifosfamide for recurrent breast cancer. | 1992 Mar |
|
Encephalopathy in ifosfamide-treated patients. | 1992 Nov |
|
Oral ifosfamide-mesna: a clinical investigation in advanced non-small-cell lung cancer. | 1992 Nov |
|
[Epileptic seizures and treatment with ifosfamide-mesna]. | 1994 |
|
Prevention of cyclophosphamide-induced hemorrhagic cystitis by glucose-mannose binding plant lectins. | 1999 Jun |
|
Pharmacological and histopathological study of cyclophosphamide-induced hemorrhagic cystitis - comparison of the effects of dexamethasone and Mesna. | 1999 Oct |
|
[Hemorrhagic cystitis related to the high-dose conditioning therapy in a bone marrow recipient]. | 2001 |
|
DICE (dexamethasone, ifosfamide, cisplatin, etoposide) infusional chemotherapy for refractory or relapsed non-Hodgkin's lymphoma (NHL). | 2001 Jul |
|
Use of dexamethasone with mesna for the prevention of ifosfamide-induced hemorrhagic cystitis. | 2003 Nov |
|
Pelvic primitive neuroectodermal tumor associated with a cluster of small round cell tumors: case report and review of current literature. | 2003 Oct |
|
Outcome after hyperbaric oxygen treatment for cyclophosphamide-induced refractory hemorrhagic cystitis. | 2003 Sep |
|
Hyperbaric oxygen therapy for cyclophosphamide induced refractory hemorrhagic cystitis in a child. | 2004 Aug |
|
Ternatin, a flavonoid, prevents cyclophosphamide and ifosfamide-induced hemorrhagic cystitis in rats. | 2004 Feb |
|
Contribution of antioxidants to preventive effect of mesna in cyclophosphamide-induced hemorrhagic cystitis in rats. | 2004 Nov |
|
A 50-year-old man with burkitt lymphoma. | 2008 Oct |
|
Acrolein and chloroacetaldehyde: an examination of the cell and cell-free biomarkers of toxicity. | 2013 Feb 25 |
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:58:56 UTC 2023
by
admin
on
Fri Dec 15 15:58:56 UTC 2023
|
Record UNII |
VHD28S0H7F
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000180854
Created by
admin on Fri Dec 15 15:58:56 UTC 2023 , Edited by admin on Fri Dec 15 15:58:56 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
Mercaptoethanesulfonic acid
Created by
admin on Fri Dec 15 15:58:56 UTC 2023 , Edited by admin on Fri Dec 15 15:58:56 UTC 2023
|
PRIMARY | |||
|
VHD28S0H7F
Created by
admin on Fri Dec 15 15:58:56 UTC 2023 , Edited by admin on Fri Dec 15 15:58:56 UTC 2023
|
PRIMARY | |||
|
SUB32737
Created by
admin on Fri Dec 15 15:58:56 UTC 2023 , Edited by admin on Fri Dec 15 15:58:56 UTC 2023
|
PRIMARY | |||
|
VHD28S0H7F
Created by
admin on Fri Dec 15 15:58:56 UTC 2023 , Edited by admin on Fri Dec 15 15:58:56 UTC 2023
|
PRIMARY | |||
|
17905
Created by
admin on Fri Dec 15 15:58:56 UTC 2023 , Edited by admin on Fri Dec 15 15:58:56 UTC 2023
|
PRIMARY | |||
|
58319
Created by
admin on Fri Dec 15 15:58:56 UTC 2023 , Edited by admin on Fri Dec 15 15:58:56 UTC 2023
|
PRIMARY | |||
|
DTXSID8023264
Created by
admin on Fri Dec 15 15:58:56 UTC 2023 , Edited by admin on Fri Dec 15 15:58:56 UTC 2023
|
PRIMARY | |||
|
100000126313
Created by
admin on Fri Dec 15 15:58:56 UTC 2023 , Edited by admin on Fri Dec 15 15:58:56 UTC 2023
|
PRIMARY | |||
|
222-167-0
Created by
admin on Fri Dec 15 15:58:56 UTC 2023 , Edited by admin on Fri Dec 15 15:58:56 UTC 2023
|
PRIMARY | |||
|
598
Created by
admin on Fri Dec 15 15:58:56 UTC 2023 , Edited by admin on Fri Dec 15 15:58:56 UTC 2023
|
PRIMARY | |||
|
3375-50-6
Created by
admin on Fri Dec 15 15:58:56 UTC 2023 , Edited by admin on Fri Dec 15 15:58:56 UTC 2023
|
PRIMARY | |||
|
1546354
Created by
admin on Fri Dec 15 15:58:56 UTC 2023 , Edited by admin on Fri Dec 15 15:58:56 UTC 2023
|
PRIMARY | RxNorm | ||
|
DB09110
Created by
admin on Fri Dec 15 15:58:56 UTC 2023 , Edited by admin on Fri Dec 15 15:58:56 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE INACTIVE -> PARENT | |||
|
METABOLITE INACTIVE -> PARENT |
MAJOR
URINE
|
||
|
METABOLITE -> PARENT |
URINE
|